Purified Modified mRNA for Cell Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating induced pluripotent stem cells (iPSCs) using viral delivery of reprogramming factors are inefficient and risk genome integration, leading to unpredictable outcomes and potential cancer, while non-viral methods are inefficient and require long periods for iPSC formation.
Innovation Solution
The use of purified single-strand mRNA molecules encoding reprogramming factors, modified with nucleosides such as pseudouridine, 5-methylcytidine, and others, to reprogram eukaryotic cells without genome integration, minimizing immune response and RNA contaminant activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral delivery methods are used to introduce reprogramming factors, then reprogramming efficiency is improved, but the risk of genome integration and cancer increases
Solution Approach 1:
The patent extracts the reprogramming function from viral vectors and implements it using purified mRNA molecules. By taking out the reprogramming factors (OCT4, SOX2, KLF4, c-MYC) from their traditional viral delivery context and delivering them as isolated mRNA, the invention achieves high reprogramming efficiency while eliminating the harmful genome integration risk associated with viral methods.
Solution Approach 2:
The patent uses modified nucleosides (such as pseudouridine and 5-methylcytidine) as intermediaries to deliver reprogramming factors. These modified nucleosides in the mRNA structure serve as mediators that protect the RNA from degradation and reduce immune recognition, enabling efficient protein expression without the hazards of viral delivery.
2Object-affected harmful factors
If non-viral delivery methods are used to introduce reprogramming factors, then genome integration risk is reduced, but reprogramming efficiency and speed decrease
Solution Approach 1:
The patent changes the chemical parameters of the mRNA by incorporating modified nucleosides (pseudouridine, 5-methylcytidine, and other canonical modified nucleosides). This parameter change transforms the mRNA from a standard, rapidly degraded form into a stable, immunomodulated form that can efficiently drive protein expression and achieve rapid reprogramming without genome integration.
Solution Approach 2:
The invention creates a composite mRNA structure by combining multiple modified nucleosides within the same RNA molecule. This composite approach, using mixtures of pseudouridine, 5-methylcytidine, and other modified nucleosides, produces an mRNA with enhanced stability and reduced immunogenicity, achieving high reprogramming efficiency through non-viral delivery.
3Device complexity
If standard mRNA is used for reprogramming, then simplicity is maintained, but immune response and RNA sensor activation increase
Solution Approach 1:
The patent modifies the chemical composition parameters of the mRNA by substituting canonical nucleosides with modified versions. This changes the physical-chemical properties of the RNA, making it less recognizable by cellular RNA sensors and reducing triggering of immune responses, while maintaining the fundamental mRNA structure and function.
Data Source
AI summary
The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.